<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Disc Medicine Inc. — News on 6ix</title>
<link>https://6ix.com/company/disc-medicine-inc</link>
<description>Latest news and press releases for Disc Medicine Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/disc-medicine-inc" rel="self" type="application/rss+xml" />
<item>
<title>Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-17</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-17</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to</description>
</item>
<item>
<title>Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at the American Society of Hematology (ASH) conference demonstrating meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhi</description>
</item>
<item>
<title>Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-receives-complete-response-200400497</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-receives-complete-response-200400497</guid>
<pubDate>Fri, 13 Feb 2026 20:04:00 GMT</pubDate>
<description>FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA indicated a need to see the results of the ongoing Phase 3 APOLLO study before making a decisionOngoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026 WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-appoints-lisa-amaya-213000051</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-appoints-lisa-amaya-213000051</guid>
<pubDate>Mon, 12 Jan 2026 21:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company’s Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at mu</description>
</item>
<item>
<title>Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-highlights-recent-achievements-133000879</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-highlights-recent-achievements-133000879</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed by an End of Phase 2 MeetingInitial data from the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study in sickle cell disease (SCD) expected in H2 2026 WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NAS</description>
</item>
<item>
<title>Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-present-44th-annual-133000787</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-present-44th-annual-133000787</guid>
<pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET. A</description>
</item>
<item>
<title>Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-presents-positive-initial-data-rally-mf-phase-2-trial-patients</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-presents-positive-initial-data-rally-mf-phase-2-trial-patients</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent</description>
</item>
<item>
<title>Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA</description>
</item>
<item>
<title>Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-presentation-initial-data-rally-mf-phase-2-trial-patients</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-presentation-initial-data-rally-mf-phase-2-trial-patients</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Disc Medicine to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-participate-upcoming-investor-conferences-2025-10-31</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-participate-upcoming-investor-conferences-2025-10-31</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-pricing-250-million-upsized-public-offering-common-stock-and</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-pricing-250-million-upsized-public-offering-common-stock-and</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-proposed-public-offering-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-proposed-public-offering-common-stock-and-pre-funded-warrants</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-provides-update-hematology-portfolio-and-outlines-near-term-business</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-provides-update-hematology-portfolio-and-outlines-near-term-business</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently</description>
</item>
<item>
<title>Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-present-data-phase-1b-trial-disc-0974-patients-chronic-kidney-disease</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-present-data-phase-1b-trial-disc-0974-patients-chronic-kidney-disease</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-receipt-fda-commissioners-national-priority-voucher-cnpv</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-receipt-fda-commissioners-national-priority-voucher-cnpv</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application</description>
</item>
<item>
<title>Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-submission-new-drug-application-nda-us-fda-accelerated</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-announces-submission-new-drug-application-nda-us-fda-accelerated</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of</description>
</item>
<item>
<title>Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors</title>
<link>https://6ix.com/company/disc-medicine-inc/news/shattuck-labs-announces-closing-of-up-to-dollar103-million-private-placement-and-appointments-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/shattuck-labs-announces-closing-of-up-to-dollar103-million-private-placement-and-appointments-to-board-of-directors</guid>
<pubDate>Tue, 26 Aug 2025 10:30:00 GMT</pubDate>
<description>— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 202</description>
</item>
<item>
<title>Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-second-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/disc-medicine-reports-second-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by</description>
</item>
<item>
<title>OrbiMed Promotes Mona Ashiya to General Partner</title>
<link>https://6ix.com/company/disc-medicine-inc/news/orbimed-promotes-mona-ashiya-to-general-partner</link>
<guid isPermaLink="true">https://6ix.com/company/disc-medicine-inc/news/orbimed-promotes-mona-ashiya-to-general-partner</guid>
<pubDate>Tue, 22 Jul 2025 13:15:00 GMT</pubDate>
<description>OrbiMed, a leading global healthcare investment firm, today announced the promotion of Mona Ashiya, Ph.D., to general partner. Ashiya joins the company's eight existing general partners as a management company owner and leader of the firm.</description>
</item>
</channel>
</rss>